This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Usmani, Saad
| Item Type | Name |
|
Concept
|
Thalidomide
|
|
Academic Article
|
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
|
|
Academic Article
|
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
|
|
Academic Article
|
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
|
|
Academic Article
|
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.
|
|
Academic Article
|
Thalidomide and its analogues in the treatment of Multiple Myeloma.
|
|
Academic Article
|
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
|
|
Academic Article
|
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
|
|
Academic Article
|
How long can we let the myeloma smolder?
|
|
Academic Article
|
Novel drug combinations for the management of relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Maintenance lenalidomide after transplantation: How much is enough?
|
|
Academic Article
|
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
|
|
Academic Article
|
Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.
|
|
Academic Article
|
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Practical Considerations in Managing Relapsed Multiple Myeloma.
|
|
Academic Article
|
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
|
|
Academic Article
|
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
|
|
Academic Article
|
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
|
|
Academic Article
|
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
|
|
Academic Article
|
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
|
|
Academic Article
|
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse.
|
|
Academic Article
|
Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.
|